M. Briley

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
M S Briley, M. S. Briley, M Briley, M. Briley, Michael Briley, Michael S. Briley, Mike Briley
Publication record
201 papers · 13,565 citations · H-index 45

PAPERS

The importance of norepinephrine in depression
2011347 citationsauthor #2
The noradrenergic symptom cluster: clinical expression and neuropharmacology
201160 citationsauthor #2
Noradrenergic symptom cluster in depression
20116 citationsauthor #2
Milnacipran: recent findings in depression
20107 citationsauthor #2
Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
201034 citationsauthor #1
Drugs to treat fibromyalgia - the transatlantic difference.
201028 citationsauthor #1
Why psychiatrists should not ignore pain in their patients—focus on fibromyalgia?
20092 citationsauthor #2
Review: Problems associated with long-term treatment with selective serotonin reuptake inhibitors
200989 citationsauthor #3
Fibromyalgia: a complex syndrome requiring a multidisciplinary approach
200939 citationsauthor #2
Announcements
20090 citationsauthor #2
The management of depression: An international naturalistic survey
20085 citationsauthor #4
Treatment of Comorbid Pain with Serotonin Norepinephrine Reuptake Inhibitors
200821 citationsauthor #1
Resolution of sexual dysfunction during acute treatment of major depression with milnacipran
200834 citationsauthor #3
Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan
20072 citationsauthor #2
Antidepressants in the treatment of fibromyalgia
200643 citationsauthor #2
Neuropharmacology of a new potential anxiolytic compound, F 2692, 1-(3′-trifluoromethyl phenyl) 1, 4-dihydro 3-amino 4-oxo 6-methyl pyridazine
20057 citationsauthor #3
Ex vivo inhibitory effect of the 5-HT uptake blocker citalopram on 5-HT synthesis
200513 citationsauthor #2
The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze
200520 citationsauthor #2
Neuropharmacology of a new potential anxiolytic compound, F 2692, 1-(3′-trifluoromethyl phenyl) 1, 4-dihydro 3-amino 4-oxo 6-methyl pyridazine
20055 citationsauthor #5
Effect of serotonergic lesion on “anxious” behaviour measured in the elevated plus-maze test in the rat
200572 citationsauthor #1
SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants
2005455 citationsauthor #4
Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats
200573 citationsauthor #2
Clinical experience with dual action antidepressants in different chronic pain syndromes
200484 citationsauthor #1
The epidemiology of pain in depression
2004274 citationsauthor #2
Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant milnacipran
200418 citationsauthor #4
3H-Rauwolscine binding in platelets from depressed patients and healthy volunteers
20048 citationsauthor #2
Understanding pain in depression
2004131 citationsauthor #2
3H-Imipramine binding and serotonin uptake in platelets from untreated depressed patients and control volunteers
200425 citationsauthor #2
Sedation, an unpleasant, undesirable and potentially dangerous side‐effect of many psychotropic drugs
200443 citationsauthor #2
Psychopharmacology of midalcipran, 1-phenyl-1-diethyl-amino-carbonyl-2-aminomethylcyclopropane hydrochloride (F 2207), a new potential antidepressant
200424 citationsauthor #3
High-affinity 3H-imipramine binding in platelets from untreated and treated depressed patients compared to healthy volunteers
200416 citationsauthor #3
Fibromyalgia syndrome: an overview of potential drug targets.
200311 citationsauthor #1
Re: Surgeon-controlled ultrasound-guided core biopsies in the breast-a prospective study and a new use for surgeons in the clinic.
20030 citationsauthor #3
New hope in the treatment of painful symptoms in depression.
200341 citationsauthor #1
Five years experience of prescribing milnacipran: An interview with Didier Papeta (Head of Psychiatry, General Military Hospital, Brest, France)
20032 citationsauthor #1
Pharmacodynamics of milnacipran in young and elderly volunteers.
200247 citationsauthor #4
The green evolution of psychotropic drugs.
20020 citationsauthor #1
When is a breast lump a lump? How good are general practitioners (GP) in their diagnosis, and how good are Breast Surgeons?
20010 citationsauthor #5
The role and histological classification of needle core biopsy in comparison with fine needle aspiration cytology in the preoperative assessment of impalpable breast lesions
200186 citationsauthor #8
Overview: pharmacogenomics of psychiatric disorders--separating the dreams from the realities.
20010 citationsauthor #1
Where are the new therapies for anxiety and obsessive-compulsive disorders?
20013 citationsauthor #2
Functional Neuropharmacology of Compounds Acting at 5-HT1B/D Receptors
200016 citationsauthor #1
Present and future anxiolytics.
200011 citationsauthor #1
Diagnosis and treatment of depression in late life
19991 citationsauthor #1
Antidepressant Therapy at the Dawn of the Third Millennium
199942 citationsauthor #1
How common is poor outcome in depression
19980 citationsauthor #1
What constitutes ‘recovery’ from depression?
19980 citationsauthor #1
Is Full Recovery from Depression Possible: pocketbook
19981 citationsauthor #1
The economic impact of recurrent depression
19980 citationsauthor #1
Pasteur Euroconference on future therapies for an anxious world.
19980 citationsauthor #1
Factors affecting outcome of depression
19980 citationsauthor #1
Long-term treatment of depression
19981 citationsauthor #1
Serotonin transmission in depression and anxiety disorders - new insights and potential new drugs
19980 citationsauthor #1
Milnacipran, a new specific serotonin and noradrenaline reuptake inhibitor.
199830 citationsauthor #2
5-HT1B/1D Receptors in Psychiatry and Neurology
19982 citationsauthor #1
Milnacipran, a Well-Tolerated Specific Serotonin and Norepinephrine Reuptake Inhibiting Antidepressant
199810 citationsauthor #1
Neurochemical and Behavioral Effects Related to 5-HT1B/1D Receptors
19980 citationsauthor #1
Specific serotonin and noradrenaline reuptake inhibitors (SNRIs). A review of their pharmacology, clinical efficacy and tolerability
199826 citationsauthor #1
Nouveaux derives de la piperidine substitues en position 4 par un groupe imidazolidin-2-on-1-yl-ethyl, tetrahydropyrimidin-2-on-1-yl-ethyl, et 1,3-dia-zepin-2-on-1-yl-ethyl, et leurs applications comme antagonistes des recepteurs alpha-2 adrenergiques
19970 citationsauthor #4
5-HT autoreceptors in the regulation of 5-HT release from guinea pig raphe nucleus and hypothalamus.
199741 citationsauthor #2
Effects of Milnacipran and Pindolol on Extracellular Noradrenaline and Serotonin Levels in Guinea Pig Hypothalamus
199757 citationsauthor #2
Use of milnacipran and its derivatives for the preparation of a medicament for the treatment of certain psychiatric disorders
19970 citationsauthor #1
Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability
1997136 citationsauthor #5
From Dirty Drugs to Hyperselectivity and Part Way Back Again
19972 citationsauthor #1
The Role of Noradrenaline in Depression and its Therapy
19971 citationsauthor #1
Antidepressant Properties of Specific Serotonin—Noradrenaline Reuptake Inhibitors
199717 citationsauthor #1
Milnacipran, a double noradrenaline and 5-HT reuptake inhibiting antidepressant increases cerebral extracellular monoamine levels
19962 citationsauthor #2
News imidazolidinone, pyrimidinones and 1,3-diazepin-2 -one, their preparation and their applications in therapeutics
19960 citationsauthor #4
P-23 Pharmacokinetic-pharmacadynamic relationship of milnacipran on platelet uptake model
19960 citationsauthor #3
Synergistic increases of noradrenaline and 5-HT neurotransmission induced by milnacipran with pindolo
19960 citationsauthor #2
Preclinical pharmacology of milnacipran
199675 citationsauthor #1
P-5 Milnacipran, a new well-balanced double noradrenaline and serotonin reuptake inhibitor: Biochemical and pharmacological characteristics.
19960 citationsauthor #1
Lack of effect of repeated administration of milnacipran, a double noradrenaline and serotonin reuptake inhibitor, on the beta-adrenoceptor-linked adenylate cyclase system in the rat cerebral cortex.
199615 citationsauthor #4
Milnacipran, a double noradrenaline and serotonin reuptake inhibiting antidepressant
19961 citationsauthor #1
New benzodioxanes and 1- (2h) -benzopyrannes, their preparation and their use as medicine
19960 citationsauthor #4
Efficacy and tolerability of milnacipran: an overview
199673 citationsauthor #4
Can transvaginal ultrasound scanning in post menopausal women reduce the need for endometrial biopsy
19960 citationsauthor #1
Effect of mefenorex on 5-HT release: studies in vitro on rat hypothalamic slices and in vivo by microdialysis.
19954 citationsauthor #3
In vitro and in vivo activity of 1-(1-naphthyl)piperazine at terminal 5-HT autoreceptors in guinea-pig brain
19955 citationsauthor #2
Flexible 1-[(2-aminoethoxy)alkyl]-3-ar(o)yl(thio)ureas as novel acetylcholinesterase inhibitors. Synthesis and biochemical evaluation.
199511 citationsauthor #5
Flexible 1-((2-Aminoethoxy)alkyl)-3-ar(o)yl(thio)ureas as Novel Acetylcholinesterase Inhibitors. Synthesis and Biochemical Evaluation.
19950 citationsauthor #5
5-HT1D AUTORECEPTORS IN THE ACTION OF ANTIDEPRESSANT DRUGS
19940 citationsauthor #1
Novel (2‐(4‐Piperidinyl)ethyl)(thio)ureas: Synthesis and Antiacetylcholinesterase Activity.
19943 citationsauthor #7
The use of efaroxan and derivatives thereof for the manufacture of a medicament for the treatment of Parkinson's disease
19940 citationsauthor #2
Elevated plus maze activity and serotonergic neurotransmission in Fawn-Hooded rats
19940 citationsauthor #1
Imlink and continuing medical education: the use of an image transfer system to broadcast teaching cases nationally.
19944 citationsauthor #1
Use of Efaxoran and derivatives thereof for the preparation of medicaments intended for the treatment of neurodegenerative sygdo
19940 citationsauthor #2
Autoradiographic characterization of binding sites for [3H]milnacipran, a new antidepressant drug, and their relationship to the serotonin transporter in rat brain.
19945 citationsauthor #3
Novel [2-(4-piperidinyl)ethyl](thio)ureas: synthesis and antiacetylcholinesterase activity.
199430 citationsauthor #7
An unexpected twist
19931 citationsauthor #1
Case of the month: an unexpected twist.
19930 citationsauthor #1
Does 5-carboxamidotryptamine-induced turning in guinea-pigs involve 5-HT1D autoreceptors?
19935 citationsauthor #2
5-HT and antidepressants: in vitro and in vivo release studies.
199320 citationsauthor #1
News arylpiperazines indole derivatives, their preparation and their therapeutic use.
19930 citationsauthor #3
The unique effect of methiothepin on the terminal serotonin autoreceptor in the rat hypothalamus could be an example of inverse agonism
199330 citationsauthor #2
IS ANXIETY ASSOCIATED WITH A HYPER- OR HYPO-SEROTONERGIC STATE?
19929 citationsauthor #1
Effect of antidepressant drugs on monoamine synthesis in brain in vivo.
199259 citationsauthor #2
AUTOREGULATION OF NORADRENALINE RELEASE AND ANTIDEPRESSANT ACTIVITY.
19920 citationsauthor #2
Use of idazoxan and its derivatives for the preparation of a medicament for the treatment of Parkinson's disease and its development.
19920 citationsauthor #2
5-HT: on the psychiatrist's couch.
19925 citationsauthor #1

TIMELINE

1970 67 citations

1974 50 citations

1975 40 citations

1977 34 citations

1978 250 citations

1979 696 citations

1980 1,189 citations

1981 814 citations

1982 288 citations

1983 127 citations

1984 273 citations

1985 5,982 citations

1986 56 citations

1987 331 citations

1988 131 citations

1989 16 citations

1990 206 citations

1991 81 citations

1992 73 citations

1993 56 citations

1994 42 citations

1995 20 citations

1996 166 citations

1997 254 citations

1998 70 citations

1999 43 citations

2000 27 citations

2001 89 citations

2002 47 citations

2003 54 citations

2004 623 citations

2005 645 citations

2006 43 citations

2007 2 citations

2008 60 citations

2009 130 citations

2010 69 citations

2011 413 citations

Unknown 13 citations

M. Briley

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT